Symbolbild · KI-generiert
Lexeo Therapeutics, Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Lexeo Therapeutics, Inc. | LXEO | NASDAQ | 324 Mio. USD |
| CapsoVision, Inc. | CV | NASDAQ | 329 Mio. USD |
| Palisade Bio, Inc. | PALI | NASDAQ | 329 Mio. USD |
| Lyell Immunopharma, Inc. | LYEL | NASDAQ | 317 Mio. USD |
| Scribe Therapeutics Inc. | SCTX | NASDAQ | 315 Mio. USD |
| Fennec Pharmaceuticals Inc. | FENC | NASDAQ | 334 Mio. USD |
| Agenus Inc. | AGEN | NASDAQ | 336 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.